Despite Recent Gains, Altimmune Insiders Are Still Down US$29k
This article states that despite some recent positive share price movement, Altimmune insiders are still collectively down US$29k on their investments over the last year. This is primarily due to a significant share price decline, meaning recent share purchases by insiders have not yet compensated for previous losses.
Altimmune director Gill buys $31k in company stock
Altimmune Inc. Director John Gill purchased 9,200 shares of company stock for over $31,000, increasing his direct ownership to 21,700 shares. This insider buying occurred despite the company reporting a larger-than-expected loss and revenue shortfall in Q4 2025, and some analyst concerns about potential overvaluation. However, several firms like Jefferies and Truist Securities maintain "Buy" ratings, citing the potential of its lead asset, pemvidutide.
Altimmune (ALT) director makes open-market share purchase
Altimmune, Inc. director John Gill purchased 9,200 shares of common stock on the open market at a weighted average price of $3.4076 per share, totaling approximately $31,350. This transaction increases his direct holdings to 21,700 shares. The purchase, made in multiple trades between $3.4050 and $3.4080, signals a positive sentiment from an insider.
Altimmune Stock Outlook Brightens as Analysts Raise Price Targets
Altimmune (ALT) stock is experiencing a positive upswing after analysts raised price targets, some as high as $25, citing progress in their MASH program and the potential of pemvidutide for metabolic disorders. Despite a high price-to-sales ratio and profitability challenges, the company demonstrates strong liquidity and technical bullish momentum. While a recent stock drop was deemed excessive, robust financial backing and ongoing clinical developments support a positive long-term outlook for the biotech firm.
Gitlab, Altimmune, Cheniere, Pacific Biosciences, Hercules Shock Wall Street
Insiders have recently made significant trades in five companies: Gitlab (GTLB), Altimmune (ALT), Cheniere (LNG), Pacific Biosciences (PACB), and Hercules Capital (HTGC). While Gitlab and Pacific Biosciences saw insider selling, indicating potential reevaluation by investors, Altimmune and Hercules Capital experienced substantial insider buying, signaling strong confidence in their future prospects. Cheniere, however, witnessed a massive multi-executive cash-out, raising questions about its outlook.
Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Rating of "Moderate Buy" from Brokerages
Altimmune, Inc. (NASDAQ:ALT) has received a "Moderate Buy" consensus rating from brokerages, with an average 1-year price target of $18.00 from ten analysts, despite individual targets ranging from $13.00 to $25.00. The company's CEO recently increased his stake, and institutional investors own a significant portion of the stock. Altimmune reported a quarterly EPS loss of $0.27, missing estimates, and trades near its 52-week low.
Insider Buying: Gregory Weaver Acquires 10,000 Shares of Altimmune Inc (ALT)
Gregory Weaver, CFO of Altimmune Inc (ALT), recently purchased 10,000 shares of the company, increasing his total holdings to 38,078 shares. This transaction, occurring on April 1, 2026, reflects a broader positive trend of insider buying at the clinical-stage biopharmaceutical company, with nine insider buys and no sells over the past year. The shares were trading at $3.15, valuing the company at $405.929 million, and this consistent buying by Weaver suggests confidence in Altimmune's future prospects.
Altimmune (NASDAQ: ALT) CEO adds 15,000 shares in open-market buy
Altimmune, Inc. President and CEO Jerome Benedict Durso recently purchased 15,000 shares of the company's common stock in an open-market transaction at $3.14 per share. This acquisition increased his direct holdings to 47,500 shares. The Form 4 filing indicates a neutral impact with positive sentiment, highlighting insider confidence in the company's prospects.
Altimmune (ALT) CFO adds 10,000 shares in open-market stock purchase
Altimmune, Inc.'s Chief Financial Officer, Gregory L. Weaver, purchased 10,000 shares of common stock in an open-market transaction on April 1, 2026. The shares were acquired at a weighted average price of $3.1499 per share, increasing his direct holdings to 38,078 shares. This insider buying activity is seen as a positive signal to investors, suggesting confidence in the company's future.
ALT (Altimmune) Shares Outstanding (Diluted Average) : 105.82 Mil (As of Dec. 2025)
This article reports Altimmune's (ALT) diluted average shares outstanding as 105.82 million as of December 2025. It explains that shares outstanding are shares held by investors and are used to calculate income statement items like EPS. The article provides historical data and charts for Altimmune's shares outstanding and offers a competitive comparison within the Biotechnology industry.
ALT (Altimmune) 5-Year RORE % : -16.56% (As of Dec. 2025)
Altimmune Inc. (ALT) has a 5-Year Return on Retained Earnings (RORE) of -16.56% as of December 2025, which ranks worse than 60.59% of companies in the Biotechnology industry. RORE indicates a company's efficiency in reinvesting its profits after dividend payments to generate growth. The company's GF Score is 39/100, and it has 4 warning signs for investors to consider.
Altimmune Inc. (ALT) Stock Price | Live Quotes & Charts | NASDAQ
This NASDAQ page provides live quotes and charts for Altimmune Inc. (ALT) stock, showing its current price of $3.02 with a daily decrease of 5.30%. The article notes a lack of analyst ratings and earnings information for the company but offers free trade alerts and insights from an AI-driven analysis platform.
ALT (Altimmune) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2025)
This article reports that Altimmune Inc (NAS:ALT) has a Capex-to-Operating-Cash-Flow ratio of 0.00 as of December 2025. GuruFocus rates Altimmune with a GF Score of 39/100, noting 4 warning signs for investors to review. The Capex-to-Operating-Cash-Flow ratio, which indicates how much cash flow from operations is dedicated to capital expenditures, is not calculated when operating cash flow is negative, as was the case for Altimmune's Q4 2025.
Jefferies reiterates Buy on Altimmune stock, keeps $28 target
Jefferies has reiterated a "Buy" rating and a $28 price target for Altimmune Inc. (NASDAQ:ALT), emphasizing the company's entry into a Phase 3 execution stage with its Pemvi drug for MASH. Despite recent financial challenges, including an EPS miss and negative free cash flow, Jefferies highlights the strategic design of the Phase 3 trial and positive balance sheet aspects, such as more cash than debt. This comes amid varied analyst perspectives, with some expressing optimism about Pemvi's market potential and others noting the competitive MASH landscape.
Vanguard subsidiaries disaggregate holdings; Altimmune (NASDAQ: ALT) showing 0 shares
The Vanguard Group filed an Amendment No. 3 to a Schedule 13G/A, declaring 0 beneficially owned shares and 0% of the class in Altimmune Inc. This update reflects an internal realignment within Vanguard, leading certain subsidiaries to report their beneficial ownership separately as per SEC Release No. 34-39538. The filing indicates that Vanguard no longer has or is deemed to have beneficial ownership over securities now reported by these disaggregated entities.
ALT (Altimmune) EPS without NRI : $-1.01 (TTM As of Dec. 2025)
Altimmune (ALT) reported an EPS without Non-Recurring Items (NRI) of $-1.01 for the trailing twelve months (TTM) ended December 2025, and $-0.27 for the quarter ended December 2025. The company's 3-year average EPS (NRI) Growth Rate was 17.90% per year, ranking better than 51.83% of Biotechnology companies. GuruFocus rates Altimmune with a GF Score™ of 40/100, noting 4 warning signs for investors to review.
ALT Pemvidutide Uncovered: How It Stands Apart in MASH
Altimmune's pemvidutide is an innovative dual glucagon and GLP-1 receptor agonist targeting MASH, AUD, and ALD, positioning itself to address the urgent need for new therapies. The drug's unique dual-action biology and EuPort technology aim to improve tolerability and effectiveness in liver disease treatment. With promising Phase IIb results, ALT is progressing to Phase III trials, while facing inherent risks associated with relying on a single drug candidate and intense market competition.
Altimmune Stock: Balanced Perspective With Major Catalysts Expected in 2026
Altimmune's 2026 outlook is heavily reliant on its drug candidate, pemvidutide, currently in trials for MASH, AUD, and ALD. Key milestones include a global Phase III trial for MASH and top-line results from the Phase II RECLAIM trial for AUD, both expected in 2026. While the company has sufficient cash through 2028, further capital will likely be needed for the MASH Phase III program, potentially leading to shareholder dilution amidst a competitive market.
ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms
Altimmune (ALT) is advancing its drug pemvidutide, a balanced glucagon/GLP-1 dual receptor agonist, into a competitive phase III MASH drug race, with significant clinical readouts expected in 2026 across MASH, alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company emphasizes pemvidutide's liver-directed benefits, weight loss capabilities, and tolerability strategy as differentiators against existing and pipeline GLP-1 and other MASH treatments. Investors are closely watching the 2026 timeline for key data readouts, potential financing needs, and the drug's positioning for accelerated approval, which could make Altimmune an attractive candidate for licensing or takeover.
Altimmune Stock: Neutral Outlook With Big 2026 Catalysts
Altimmune (ALT) is focusing on its drug pemvidutide, a glucagon/GLP-1 dual receptor agonist, with significant milestones expected in 2026 across MASH, AUD, and ALD. While the company has cash runway until 2028, further capital will likely be needed to fund its Phase III MASH program, creating potential dilution risk for investors. Competition is strong in all therapeutic areas, with major players like Novo Nordisk and Eli Lilly already established in metabolic medicine.
Altimmune Stock: Balanced Perspective With Major Catalysts Expected in 2026
Altimmune (ALT) is heavily relying on its lead candidate, pemvidutide, for its future success, with major catalysts expected in 2026. These include a global phase III trial for MASH and top-line results from the phase II RECLAIM trial for alcohol use disorder (AUD) in Q3 2026. While the company has sufficient cash runway into 2028, further capital will likely be needed to fund the MASH phase III program, posing a dilution risk for investors.
HC Wainwright bullish on Altimmune (ALT) amid growing focus on treatments for metabolic and liver diseases
HC Wainwright has reiterated its "Buy" rating and $25 price target for Altimmune (ALT) due to increasing clinical and commercial interest in treatments for metabolic and liver diseases. The firm highlights Altimmune's pemvidutide as a promising GLP-1/glucagon dual agonist for obesity and MASH, with upcoming Phase 2 data expected to provide key insights into its efficacy and safety. This positive outlook positions Altimmune favorably within a rapidly evolving biopharmaceutical landscape.
H.C. Wainwright Bullish on Altimmune (ALT) Amid Growing Focus on Treatments for Metabolic and Liver Diseases
H.C. Wainwright has maintained a "Buy" rating on Altimmune (ALT) and raised its price target to $25 from $12, citing optimism around the company's MASH program and pipeline expansion. Altimmune's strategic focus on treatments for metabolic and liver diseases, particularly its pemvidutide for NASH and obesity, is highlighted as a key driver. Analysts from B. Riley also maintain a "Buy" rating, noting the drug's differentiation in Phase 3 trials and upcoming Phase 2 data.
ALT SEC Filings - Altimmune 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to Altimmune (ALT) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, and 8-K material event reports. It highlights recent filings such as insider trading activities and positive topline data from the IMPACT Phase 2b trial for pemvidutide, which showed significant MASH resolution and weight loss. The platform offers AI-powered tools to summarize filings and extract key information for investors.
Truist initiates Altimmune stock coverage with buy rating on drug potential
Truist Securities has initiated coverage on Altimmune Inc. with a buy rating and a price target of $12.00, citing the potential of its lead drug, pemvidutide, for treating MASH and liver-related diseases. The firm forecasts peak adjusted revenue of $600 million for pemvidutide, while acknowledging high risk but high reward for its development in alcohol use disorder. This comes despite Altimmune reporting a larger-than-expected loss in Q4 2025 and mixed analyst sentiment on its competitive position.
Truist initiates Altimmune stock coverage with buy rating on drug potential
Truist Securities has initiated coverage on Altimmune Inc. (NASDAQ:ALT) with a buy rating and a price target of $12.00, citing the strong potential of its primary drug candidate, pemvidutide, for treating MASH and liver-related diseases. The firm anticipates pemvidutide's dual-acting mechanism to offer improved efficacy compared to existing treatments like Wegovy. Despite a recent earnings miss for Q4 2025, analysts maintain a bullish outlook on Altimmune's strategic focus and significant market opportunities.
Altimmune (NASDAQ:ALT) Now Covered by Analysts at Truist Financial
Truist Financial initiated coverage on Altimmune (NASDAQ:ALT) with a "Buy" rating and a $12 price target, indicating a substantial potential upside. Despite this and other bullish analyst ratings (with a consensus "Moderate Buy" and $18 target), Altimmune remains unprofitable, missed its recent EPS estimate, and trades around $3.42. Insiders, including the CEO, have recently bought shares, and institutional investors own a significant portion of the company's stock.
Truist initiates Altimmune stock coverage with buy rating on drug potential
Truist Securities has initiated coverage on Altimmune Inc. with a buy rating and a price target of $12.00, citing the potential of its lead drug, pemvidutide, for treating MASH and liver-related diseases. The firm projects pemvidutide could achieve peak worldwide adjusted revenue of approximately $600 million. This positive outlook comes despite Altimmune reporting a larger-than-expected loss per share and revenue shortfall in its recent fourth-quarter 2025 earnings.
What is HC Wainwright's Estimate for Altimmune Q1 Earnings?
HC Wainwright has revised its Q1 2026 earnings estimates for Altimmune (NASDAQ:ALT), projecting a smaller loss per share of ($0.23) compared to the previous forecast of ($0.27). The firm maintains a "Buy" rating and a $25.00 price target for the stock, despite some longer-term earnings outlooks being cut. This update comes as Altimmune recently reported an earnings miss for its latest quarter, with a loss of ($0.27) per share against analyst expectations.
Altimmune (FRA:3G0) NonCurrent Deferred Revenue : €0.14 Mil (As of Dec. 2025)
Altimmune's non-current deferred revenue was €0.14 million as of December 2025. This metric is used by GuruFocus to assess the company's financial health, where Altimmune currently holds a GF Score of 38/100, indicating it is significantly overvalued with four warning signs for investors. The article details the definition of non-current deferred revenue, provides historical financial data, and offers context within the biotechnology industry, while encouraging readers to consider other financial metrics for a comprehensive view.
H.C. Wainwright raises Altimmune stock price target on MASH focus
H.C. Wainwright has increased its price target for Altimmune Inc. (NASDAQ:ALT) to $25 from $12, maintaining a Buy rating due to the company's focus on a MASH pivotal program and potential from alcohol-related disease programs. The biotech firm also has a strengthened balance sheet and plans to initiate a global Phase 3 trial for pemvidutide in MASH in 2026. Despite positive developments, Altimmune recently reported disappointing Q4 2025 earnings with a larger-than-expected loss per share and significantly missed revenue forecasts, and faces strong competition in the MASH treatment market.
Altimmune (ALT) 2026 proxy details share and ESPP increases
Altimmune's 2026 proxy statement outlines proposals for its virtual annual meeting on April 16, 2026, including the election of nine directors, ratification of Ernst & Young LLP as auditor, and an advisory vote on executive compensation. Key proposals involve increasing authorized common stock from 200 million to 400 million shares and expanding the Employee Stock Purchase Plan reserve from 403,500 to 1,108,827 shares, aimed at providing flexibility for future corporate needs, financing, and employee incentives. The company emphasizes its commitment to shareholder value creation through its compensation philosophy and strategic progression in late-stage biotechnology development.
Altimmune (NASDAQ:ALT) Price Target Raised to $25.00 at HC Wainwright
HC Wainwright has increased its price target for Altimmune (NASDAQ:ALT) to $25.00 from $12.00, maintaining a "buy" rating for the stock. Despite a recent quarterly EPS miss and negative margins, insider buying has been observed, and institutional investors own a significant portion of the company. Other analysts have a mixed view, with an average target price of $19.20.
Altimmune (ALT) Sees Price Target Raised by HC Wainwright & Co. to $25 | ALT Stock News
HC Wainwright & Co. has significantly increased its price target for Altimmune (ALT) from $12.00 to $25.00, reiterating a Buy rating. This substantial increase of 108.33% reflects a strong positive outlook for the biopharmaceutical company, which is developing therapies for liver diseases with its key candidate pemvidutide. The average one-year price target from 10 analysts for Altimmune is $17.90, suggesting a potential upside of 397.91% from its current price.
Does Altimmune (ALT) have the potential to rally 229.28% as Wall Street analysts expect?
This article discusses whether Altimmune (ALT) has the potential for a significant stock rally, as projected by Wall Street analysts. It highlights the optimistic analyst expectations for the company's stock performance. The article implies a deeper dive into the reasons behind these projections and Altimmune's current market position.
Altimmune Touts Pemvidutide Progress, Targets MASH Phase 3 Start and Q3 AUD Readout at Barclays Chat
Altimmune discussed the progress of its pemvidutide programs during a Barclays fireside chat, highlighted by upcoming catalysts in 2026, including a planned Phase 3 start for metabolic dysfunction-associated steatohepatitis (MASH) and a Q3 top-line readout for the alcohol use disorder (AUD) Phase 2 trial. The company emphasized pemvidutide's potential differentiation in MASH with early resolution and anti-fibrotic signals, and its unique mechanism focusing on liver activity and lean mass preservation. Altimmune is also focusing on strengthening its balance sheet and exploring strategic partnerships to support late-stage development.
ALT (Altimmune) NonCurrent Deferred Revenue : $0.16 Mil (As of Dec. 2025)
This article provides financial data for Altimmune Inc. (ALT), specifically its NonCurrent Deferred Revenue, which was $0.16 million as of December 2025. It explains what NonCurrent Deferred Revenue represents and how Altimmune's current figure compares to its historical data and industry peers. The article also notes Altimmune's GF Score™ of 38/100 and highlights four warning signs for investors.
ALT Stock Price, Quote & Chart | ALTIMMUNE INC (NASDAQ:ALT)
Altimmune Inc. (NASDAQ:ALT) stock is currently priced at $3.5 USD, showing a significant decrease over the past month and year. The company, focused on developing peptide-based therapeutics for obesity and liver diseases, has low technical and fundamental ratings from ChartMill. While analysts generally forecast a substantial price increase, Altimmune reported mixed Q4 earnings, missing EPS but beating revenue expectations.
Altimmune (NASDAQ: ALT) CEO buys 20,000 shares in open market
Altimmune, Inc. (NASDAQ: ALT) CEO Jerome Benedict Durso has purchased 20,000 shares of common stock in the open market. The shares were acquired at a weighted average price of $3.5395, increasing his direct ownership to 32,500 shares. This transaction, reported via a Form 4 SEC filing, is viewed with a positive sentiment.
Gregory Weaver Acquires 5,000 Shares of Altimmune (NASDAQ:ALT) Stock
Altimmune's CFO, Gregory Weaver, recently purchased 5,000 shares of the company's stock for $17,700, increasing his total holdings to 28,078 shares. The acquisition took place on March 6th at an average price of $3.54 per share. This insider buying comes as Altimmune's stock has traded in a 52-week range of $2.90–$7.73, and analysts hold a mixed view with a consensus "Hold" rating and a target price of $16.60, despite the company reporting recent quarterly losses.
Altimmune CFO Weaver buys $17,700 in shares
Altimmune's CFO, Gregory L. Weaver, purchased 5,000 shares of the company's common stock for $17,700 amidst a nearly 15% stock decline. This transaction increased his direct ownership to 28,078 shares. The news follows a larger-than-expected Q4 2025 loss and revenue shortfall, as well as a "Market Perform" rating from William Blair due to a lack of clear clinical differentiation for pemvidutide in the competitive MASH market.
Altimmune CEO Durso buys $70,790 in shares
Altimmune (NASDAQ:ALT) CEO Jerome Benedict Durso recently purchased 20,000 shares of the company's common stock for a total of $70,790. This insider buying occurred as the stock experienced a 15% decline over the past week and appears overvalued according to InvestingPro analysis. The company also recently reported lower-than-expected Q4 2025 earnings and revenue, alongside a Market Perform rating from William Blair regarding its Phase IIb IMPACT trial.
Altimmune CEO Durso buys $70,790 in shares
Altimmune, Inc. CEO Jerome Benedict Durso recently purchased 20,000 shares of the company's common stock for $70,790. This comes after a 15% decline in the stock's price over the past week and follows a disappointing Q4 2025 earnings report where the company missed EPS and revenue expectations. Analysts have maintained a "Market Perform" rating due to the lack of clear clinical differentiation for its lead drug candidate in a competitive market.
Altimmune (NASDAQ: ALT) CFO buys 5,000 shares in open market
Altimmune, Inc.'s Chief Financial Officer, Gregory L. Weaver, purchased 5,000 shares of the company's common stock in an open-market transaction at a price of $3.54 per share. This transaction increases his direct ownership to 28,078 common shares. The purchase indicates a positive sentiment from the CFO regarding the company's prospects.
Altimmune (NASDAQ: ALT) boosts cash, narrows 2025 loss and plans Phase 3 MASH
Altimmune (NASDAQ: ALT) reported a narrowed net loss of $88.1 million in 2025, an improvement from $95.1 million in 2024, primarily due to reduced research and development spending. The company significantly strengthened its financial position, ending 2025 with $274.0 million in cash, which was further boosted by a $75 million offering and a $34.3 million loan in early 2026. Altimmune plans to initiate a Phase 3 MASH trial in 2026 for its lead asset, pemvidutide, which has received FDA Breakthrough Therapy Designation for MASH and Fast Track designations for MASH and AUD, with Phase 2 data for AUD expected in Q3 2026.
Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of "Hold" by Analysts
Altimmune, Inc. (NASDAQ:ALT) has received an average "Hold" recommendation from analysts, with a consensus 12-month price target of $16.60. The company's lead candidate, pemvidutide, received FDA Breakthrough Therapy designation for MASH, with a Phase 3 trial expected to start in 2026. Despite missing Q4 earnings estimates, Altimmune reported approximately $274 million in cash and completed a $75 million offering, providing a cash runway into 2028.
Altimmune (NASDAQ:ALT) Price Target Cut to $13.00 by Analysts at B. Riley Financial
B. Riley Financial has cut its price target for Altimmune (NASDAQ:ALT) from $18.00 to $13.00 but maintained a "buy" rating, indicating a potential upside of 250.40% from the current price. This adjustment follows Altimmune's Q4 earnings miss, where the company reported an EPS of ($0.27) against an expected ($0.25). Despite the earnings miss, the company is advancing its key drug candidate, pemvidutide, with a Phase 3 MASH trial planned for 2026 and has secured a cash runway into 2028.
Altimmune, Inc. (NASDAQ:ALT) Q4 2025 Earnings Call Transcript
Altimmune, Inc. (NASDAQ:ALT) discussed its Q4 2025 financial results and provided a business update, highlighting its focus on advancing PEMB, a drug targeting liver diseases like NASH. The company announced the FDA Breakthrough Therapy designation for PEMB in NASH and outlined plans for a Phase III trial, emphasizing its dual mechanism (glucagon and GLP-1 agonism) and favorable tolerability. Altimmune also detailed ongoing Phase II trials for PEMB in Alcohol Use Disorder (AUD) and Alcoholic Liver Disease (ALD), with top-line AUD data expected in Q3 2026.
Altimmune Reports FY25 Financials: Why Is Big Pharma Staying Away (NASDAQ:ALT)
Altimmune (ALT) recently reported its FY25 financials, missing analyst expectations. Despite advancing pemvidutide, a dual GLP-1/glucagon agonist, into a pivotal Phase 3 MASH trial and securing substantial cash to fund operations, the company has not attracted strategic partnerships. This raises concerns about market entry timing, competitive landscape given rapid GLP-1 commoditization, and its ability to differentiate itself against established competitors.
William Blair Maintains Market Perform on ALT (Altimmune, Inc.) March 2026
William Blair has reiterated a "Market Perform" rating for Altimmune, Inc. (ALT) on March 5, 2026, indicating a neutral view on the stock without providing a specific price target. This decision follows Altimmune's Q4 2025 results, leading to a -6.54% stock price drop and suggesting investors need to monitor clinical progress and cash flow closely given the biotech's mid-cap status. Meyka AI independently rates ALT with a grade of B, aligning with the balanced outlook.
